Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies

Research output: Contribution to journalArticlepeer-review

Standard

Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. / Lemaire, M.; D'huyvetter, Matthias; Lahoutte, T.; Van Valckenborgh, E.; Menu, E.; De Bruyne, E.; Kronenberger, P.; Wernery, U.; Muyldermans, S.; Devoogdt, N.; Vanderkerken, K.; Baatout, Sarah (Peer reviewer).

In: Leukemia, Vol. 28, No. 2, 02.2014, p. 444-447.

Research output: Contribution to journalArticlepeer-review

Harvard

Lemaire, M, D'huyvetter, M, Lahoutte, T, Van Valckenborgh, E, Menu, E, De Bruyne, E, Kronenberger, P, Wernery, U, Muyldermans, S, Devoogdt, N, Vanderkerken, K & Baatout, S 2014, 'Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies', Leukemia, vol. 28, no. 2, pp. 444-447. https://doi.org/10.1038/leu.2013.292

APA

Lemaire, M., D'huyvetter, M., Lahoutte, T., Van Valckenborgh, E., Menu, E., De Bruyne, E., Kronenberger, P., Wernery, U., Muyldermans, S., Devoogdt, N., Vanderkerken, K., & Baatout, S. (2014). Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. Leukemia, 28(2), 444-447. https://doi.org/10.1038/leu.2013.292

Vancouver

Lemaire M, D'huyvetter M, Lahoutte T, Van Valckenborgh E, Menu E, De Bruyne E et al. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. Leukemia. 2014 Feb;28(2):444-447. https://doi.org/10.1038/leu.2013.292

Author

Lemaire, M. ; D'huyvetter, Matthias ; Lahoutte, T. ; Van Valckenborgh, E. ; Menu, E. ; De Bruyne, E. ; Kronenberger, P. ; Wernery, U. ; Muyldermans, S. ; Devoogdt, N. ; Vanderkerken, K. ; Baatout, Sarah. / Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. In: Leukemia. 2014 ; Vol. 28, No. 2. pp. 444-447.

Bibtex - Download

@article{e1e9902cd0bf4a1285efb3d163d86c6d,
title = "Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies",
abstract = "Despite the implementation of autologous stem cell transplantation and novel chemotherapeutics, MM remains an incurable cancer due to the regrowth of residual cells. Thus to eliminate MRD, new therapeutic strategies are required. Nanobodies are small, recombinantly produced variable domains of Camelid heavy-chain only antibodies. Due to their favorable biochemical properties, they are valuable tools for molecular imaging and therapeutic purposes. Here we describe, as proof of principle, the generation, characterization and use of anti-idiotypic nanobodies as tools for specific targeting of MM cells in the 5T2MM murine model. After immunizing a dromedary with 5T2MM idiotype (5T2MMid) we identified high-affinity anti-idiotypic nanobodies and demonstrated their specificity in ELISA and FACS assays. Biodistribution studies and SPECT/micro-CT scans using 99mTechnetium-labeled nanobody revealed specific in vivo targeting of the 5T2MMid. Treatment of 5T2MM mice in an MRD-like stage with 177Lutetium-labelled nanobodies targeting specifically MM cells resulted in decreased circulating monoclonal protein (M-protein) and signs of reduced tumor load. Our study shows that anti-idiotypic nanobodies are a new, sensitive, specific and non-invasive tool for imaging and therapeutic purposes and provides a rationale for their clinical evaluation in MM patients.",
keywords = "Multiple myeloma, radioimmunotherapy, Nanobodies, stem cell",
author = "M. Lemaire and Matthias D'huyvetter and T. Lahoutte and {Van Valckenborgh}, E. and E. Menu and {De Bruyne}, E. and P. Kronenberger and U. Wernery and S. Muyldermans and N. Devoogdt and K. Vanderkerken and Sarah Baatout",
note = "Score = 10",
year = "2014",
month = feb,
doi = "10.1038/leu.2013.292",
language = "English",
volume = "28",
pages = "444--447",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

RIS - Download

TY - JOUR

T1 - Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies

AU - Lemaire, M.

AU - D'huyvetter, Matthias

AU - Lahoutte, T.

AU - Van Valckenborgh, E.

AU - Menu, E.

AU - De Bruyne, E.

AU - Kronenberger, P.

AU - Wernery, U.

AU - Muyldermans, S.

AU - Devoogdt, N.

AU - Vanderkerken, K.

A2 - Baatout, Sarah

N1 - Score = 10

PY - 2014/2

Y1 - 2014/2

N2 - Despite the implementation of autologous stem cell transplantation and novel chemotherapeutics, MM remains an incurable cancer due to the regrowth of residual cells. Thus to eliminate MRD, new therapeutic strategies are required. Nanobodies are small, recombinantly produced variable domains of Camelid heavy-chain only antibodies. Due to their favorable biochemical properties, they are valuable tools for molecular imaging and therapeutic purposes. Here we describe, as proof of principle, the generation, characterization and use of anti-idiotypic nanobodies as tools for specific targeting of MM cells in the 5T2MM murine model. After immunizing a dromedary with 5T2MM idiotype (5T2MMid) we identified high-affinity anti-idiotypic nanobodies and demonstrated their specificity in ELISA and FACS assays. Biodistribution studies and SPECT/micro-CT scans using 99mTechnetium-labeled nanobody revealed specific in vivo targeting of the 5T2MMid. Treatment of 5T2MM mice in an MRD-like stage with 177Lutetium-labelled nanobodies targeting specifically MM cells resulted in decreased circulating monoclonal protein (M-protein) and signs of reduced tumor load. Our study shows that anti-idiotypic nanobodies are a new, sensitive, specific and non-invasive tool for imaging and therapeutic purposes and provides a rationale for their clinical evaluation in MM patients.

AB - Despite the implementation of autologous stem cell transplantation and novel chemotherapeutics, MM remains an incurable cancer due to the regrowth of residual cells. Thus to eliminate MRD, new therapeutic strategies are required. Nanobodies are small, recombinantly produced variable domains of Camelid heavy-chain only antibodies. Due to their favorable biochemical properties, they are valuable tools for molecular imaging and therapeutic purposes. Here we describe, as proof of principle, the generation, characterization and use of anti-idiotypic nanobodies as tools for specific targeting of MM cells in the 5T2MM murine model. After immunizing a dromedary with 5T2MM idiotype (5T2MMid) we identified high-affinity anti-idiotypic nanobodies and demonstrated their specificity in ELISA and FACS assays. Biodistribution studies and SPECT/micro-CT scans using 99mTechnetium-labeled nanobody revealed specific in vivo targeting of the 5T2MMid. Treatment of 5T2MM mice in an MRD-like stage with 177Lutetium-labelled nanobodies targeting specifically MM cells resulted in decreased circulating monoclonal protein (M-protein) and signs of reduced tumor load. Our study shows that anti-idiotypic nanobodies are a new, sensitive, specific and non-invasive tool for imaging and therapeutic purposes and provides a rationale for their clinical evaluation in MM patients.

KW - Multiple myeloma

KW - radioimmunotherapy

KW - Nanobodies

KW - stem cell

UR - http://ecm.sckcen.be/OTCS/llisapi.dll/open/ezp_136677

UR - http://knowledgecentre.sckcen.be/so2/bibref/11773

U2 - 10.1038/leu.2013.292

DO - 10.1038/leu.2013.292

M3 - Article

VL - 28

SP - 444

EP - 447

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -

ID: 100788